← Back to Search

Continuous Glucose Monitoring

Real-time glucose sensor for Type 1 Diabetes (Gerber RTSA Trial)

Phase 3
Waitlist Available
Led By Patricia Fechner, MD
Research Sponsored by Seattle Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Children less than 4 years of age with Type I diabetes for at least 3 months
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
No Placebo-Only Group

Summary

The purpose of this study is to see if the use of a real-time glucose sensor improves diabetes control in young children (less than 4 years old) with Type I diabetes when they are initiated on insulin pump therapy.

Eligible Conditions
  • Type 1 Diabetes

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Real-time glucose sensorExperimental Treatment1 Intervention
Subjects wear real-time glucose sensor
Group II: ControlActive Control1 Intervention
Observational arm

Find a Location

Who is running the clinical trial?

Seattle Children's HospitalLead Sponsor
310 Previous Clinical Trials
5,231,040 Total Patients Enrolled
MedtronicIndustry Sponsor
616 Previous Clinical Trials
763,841 Total Patients Enrolled
The Gerber FoundationOTHER
43 Previous Clinical Trials
6,099 Total Patients Enrolled
~2 spots leftby Nov 2025